Clinical Trials
Articles tagged with Clinical Trials
Experimental drug shows promise for some patients with advanced prostate cancer
Screening modestly reduces prostate cancer deaths
Pediatric surgery program cuts opioid use by 56%
Winship administers first U.S. dose of investigational in vivo CAR-T therapy in multiple myeloma trial
Researchers at Winship Cancer Institute have administered the first investigational in vivo CAR-T cell therapy in the US for relapsed and refractory multiple myeloma, marking a significant milestone in next-generation cellular therapies. The therapy aims to streamline treatment processes and eliminate delays in care.
Study validates accuracy of depression screening for people with chronic pain
Survival and recurrence with GLP-1 receptor agonists in breast cancer
A cohort study found a potential association between GLP-1 RA use and improved survival rates among obese breast cancer patients with related metabolic conditions. Further evaluation of GLP-1 RA therapy in randomized clinical trials is warranted based on these findings.
Rethinking bladder cancer surveillance: Can fewer procedures be just as effective?
New post-hoc analysis examined daily oral orforglipron in adults over 65 with obesity, with or without diabetes
A new post-hoc analysis examined daily oral orforglipron treatment for obesity, with or without diabetes, in users aged 65 years and over. The study found that orforglipron significantly reduced body weight and improved blood sugar markers compared to placebo, with a similar safety profile to the overall ATTAIN clinical trial population.
Pooled analysis of trails reveals semaglutide shows good efficacy in older adults aged over 65 years
A pooled analysis of trials reveals semaglutide's safety and efficacy in individuals aged 65 years and older with obesity. The study found significant reductions in body weight and improvements in cardiometabolic risk factors, with a lower proportion of adverse events compared to placebo.
Don't rush into braces with disc displacement: experts reveal the science of sequential therapy
Cost-effectiveness of the START hospital addiction consultation service for opioid use disorder treatment
Psilocybin in the treatment of cocaine use disorder
National study seeks to improve sleep in the ICU
Genotype-guided antidepressant prescribing for patients with depression
A randomized clinical trial found that genotype-guided prescribing of SSRIs did not improve depression symptoms at 3 months but showed higher remission rates at 6 months. Future studies should focus on the long-term impact of this approach.
ERASur colorectal cancer trial reaches one-third patient accrual milestone
The ERASur clinical trial is investigating whether total ablative therapy can improve overall survival in patients with newly diagnosed, limited metastatic colorectal cancer. The study has reached one-third patient accrual milestone, signaling strong momentum.
RAS(ON) inhibitor daraxonrasib shows promising results in advanced pancreatic cancer phase 1/2 study
A phase 1/2 trial of daraxonrasib, a RAS(ON) multi-selective inhibitor, demonstrated safety and broad activity against RAS-mutant metastatic pancreatic cancer. The drug showed promising signs of activity, with approximately 30% of patients experiencing an objective response and 90% experiencing disease control.
International Progressive MS Alliance opens applications for MS Clinical and Imaging Data Resource
The International Progressive MS Alliance has launched the MS Clinical and Imaging Data Resource (MS CIDR) to accelerate understanding of MS progression. The resource contains anonymized data from 14 pharmaceutical industry clinical trials, including MRI scans and clinical visits data from over 13,000 people with progressive MS.
JMIR news: Diversity under threat as clinical trials face disruptions
Recent shifts in federal policy and funding have impacted hundreds of clinical trials designed to study disease burdens in underrepresented populations. The report highlights a systemic crisis in medical research, citing a disruption at scale that has affected over 74,000 participants across 383 trials.
Trial now enrolling seeks to answer key question: Does adding chemotherapy to hormone therapy improve survival for metastatic prostate cancer?
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
SWOG Cancer Research Network and The Hope Foundation for Cancer Research launch initiative to expand veterans’ access to cancer clinical trials
The Blanke Veterans Access to Cancer Trials Initiative aims to increase veteran participation in NCI-supported clinical trials. With more than a decade of progress, the initiative builds on grants and federal investments to strengthen Veterans Affairs Medical Center participation.
Insilico’s Rentosertib inhalation solution receives IND clearance for the world’s first AI-driven candidate to enter direct-to-lung clinical study
The INS001-055 inhalation solution is the world's first AI-driven candidate to receive IND clearance. It targets Idiopathic Pulmonary Fibrosis (IPF) with a novel molecule structure and demonstrates good tolerability, PK profiles, and dose-dependent efficacy trend.
26 Years of development of EGFR-TKIs for non-small cell lung cancer: Clinical application and resistance research progress
EGFR-TKIs have significantly improved OS and quality of life for EGFR-mutant NSCLC patients. However, ongoing research is needed to refine therapies for precise individualized treatment, addressing resistance mechanisms and optimal combination strategies.
Independent, academic cancer trials are vital to improve patient outcomes worldwide
Independent academic clinical trials are essential for improving patient outcomes, reducing inequalities in care, and strengthening healthcare systems. The Lancet Oncology Commission aims to deliver actionable recommendations to ensure these trials continue to benefit patients and society worldwide.
Care coordination and hospitalization in older adults with or at risk for cardiovascular disease
A randomized clinical trial found that proactive outreach for care coordination did not lead to better outcomes compared to usual care post-hospitalization coordination. Many participants declined the offer. The study suggests that current strategies may need to be reassessed.
Trial shows relief for those living with chronic angina
A UK-led trial found that a procedure to reopen blocked heart arteries can reduce chest pain and improve quality of life. Patients who received the treatment had more angina-free days and better quality-of-life scores than those in the placebo group.
Symptom-based dosing for neonatal opioid withdrawal
A randomized clinical trial found symptom-based dosing decreases discharge time compared to scheduled opioid taper approaches among infants with opioid withdrawal. This approach, using Eat, Sleep, Console, led to faster recovery and improved outcomes.
USC and Tempus form strategic collaboration aimed at accelerating innovation across research and patient care
The Keck School of Medicine of USC and Tempus are creating a system-wide framework to integrate clinical care, clinical trials, and research through AI-powered precision medicine tools. The goal is to enhance patient care and accelerate research and innovation.
Clinical trial of a prion disease drug candidate begins enrolling participants
A phase 1 clinical trial has started enrolling patients with symptoms of prion disease, evaluating the safety and tolerability of a small interfering RNA targeting the prion protein. The trial aims to slow disease progression and is supported by NeuroNEXT, a program of the National Institute of Neurological Disorders and Stroke.
Tumor vaccines in hepatocellular carcinoma: advances, challenges, and the path toward precision immunotherapy
Recent studies have explored tumor vaccine platforms, including peptide, dendritic cell, and nucleic acid-based vaccines. Personalized neoantigen vaccines are refining precision in HCC treatment, but challenges persist due to immunosuppressive tumor microenvironments and heterogeneity.
Brown Health researchers identify key molecule behind 'exceptional responders' with glioblastoma
Researchers discovered a powerful molecule called miR-181d that weaks tumors and helps the immune system fight back against glioblastoma. The study found that tumors in 'exceptional responders' contain higher levels of miR-181d, which blocks cancer cells' ability to repair DNA damage.
Video game improves emergency doctor trauma triage decision making
A video game developed to improve trauma triage decision making in emergency doctors has shown promising results. The game reduced under-triage rates for older patients by 49% compared to those who did not play the game, suggesting improved diagnostic abilities and adherence to guidelines.
Adaptive mobile health intervention to reduce excess gestational weight gain
A cluster-randomized trial found that an adaptive mobile health intervention effectively reduced the rate of gestational weight gain and total gestational weight gain among pregnant patients with overweight or obesity. The study suggests that technology-based interventions can be a valuable tool in managing excess weight during pregnancy.
Implanted nerve stimulation for obstructive sleep apnea found to be safe and effective in new trial
A new trial found that proximal hypoglossal nerve stimulation (pHGNS) significantly reduced breathing interruptions during sleep and improved daytime sleepiness without adverse events. The therapy, an FDA-approved alternative to nasal positive airway pressure, was found to be safe and effective in patients with moderate-to-severe obstr...
Alliance study shows new promise against locally advanced lung cancer
A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...
AACR: Zedoresertib and lunresertib combination shows promising antitumor activity
The Phase I MYTHIC trial demonstrated a strong synergy between zedoresertib and lunresertib, showing durable regressions and consistent tumor shrinkage in patients with ovarian cancer. The combination achieved an overall disease control rate of 68.5% and a molecular response rate of 47%.
First-in-human trial primes immune system to accept donor livers
A first-in-human trial shows that an infusion of immune cells derived from a donor's blood can prime the recipient's immune system to accept a donor liver, potentially reducing lifelong immunosuppression. Eight out of 13 participants achieved complete withdrawal of immunosuppression and remained off for more than three years.
Introducing JAMA+ Trials
The JAMA+ Trials platform provides a comprehensive online space for clinical trial research, featuring multimedia content and tailored resources. Recent trials published across multiple JAMA Network journals are highlighted on the platform.
UT Health San Antonio Multispecialty and Research Hospital treats first clinical trial participant in novel cancer study
The hospital is conducting a phase 2 clinical trial evaluating STAR0602, which activates the immune system to stop tumor growth across various cancers. The goal of this study is to identify safer and more effective treatments for people with advanced cancers.
New drug doubles one-year survival in pancreatic cancer trial
A phase 2 clinical trial shows that a new drug, elraglusib, when combined with chemotherapy, doubles one-year survival rates in pancreatic cancer patients, reducing the risk of death by 38%. The study is a rare success in showing a survival benefit applicable to a broad population.
Clinical trial aims to address vaginal complaints after breast cancer diagnosis
A clinical trial aims to evaluate whether laser therapy reduces vaginal dryness caused by breast cancer treatment. The study, REVITALIZE, plans to enroll approximately 250 women with a history of breast cancer who experience moderate to severe vaginal dryness.
Expanding access to palliative care for patients with advanced liver disease
A new multicenter trial demonstrates that hepatologists trained in palliative care can deliver the same quality-of-life benefits as a palliative care specialist. Quality of life improved significantly in both groups, with symptom burden and short-term mortality comparable between groups.
University of Cincinnati enrolls first patients in clinical trial for prosthetic joint infections
A new clinical trial at the University of Cincinnati is testing a peptide solution to treat prosthetic joint infections after total knee replacement. The trial aims to reduce the need for repeat surgeries and expand the treatment window beyond two weeks.
Novel, fast-acting therapy benefits patients with platelet disorder in phase 2 trial
A phase 2 clinical trial shows that mezagitamab can effectively increase platelet counts in patients with immune thrombocytopenia, improving quality of life. The investigational medication has a rapid effect, normalizing platelet counts in 48 hours.
Antidepressant unable to prevent chemotherapy-associated nerve damage
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
Alliance marks Adolescent and Young Adult Cancer Awareness Week
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
Mirtazapine for methamphetamine use disorder
In this randomized clinical trial, mirtazapine effectively reduced methamphetamine use in adults with methamphetamine use disorder. The study's findings have important implications for the treatment of this condition, which currently lacks approved pharmacotherapies.
Targeted therapy improves long-term outcomes for patients with rare mutations driving lung cancer
A phase 1/2 clinical study found that pralsetinib improved durable responses with manageable safety profiles in patients with advanced or metastatic RET fusion-positive non-small cell lung cancer. The overall response rate was 78% and median duration of response was longer in patients with the CCDC6-RET fusion gene.
Massey plays key role in helping create new therapeutic standard for patients with stage III colon cancer
A phase III clinical trial established a new treatment standard for patients with stage III colon cancer and deficient DNA mismatch repair. Immunotherapy drug atezolizumab showed significant benefits when added to chemotherapy, lowering the risk of cancer recurrence by 50%.
Large clinical RCT trial finds no clear added benefit of catheter ablation for preventing recurrent stroke in patients with atrial fibrillation
A nationwide Japanese trial found that catheter ablation did not reduce the risk of recurrent stroke or major cardiovascular events in patients with atrial fibrillation who had recently experienced a stroke. The study, which enrolled 251 patients and followed them for over three years, suggests that routine addition of catheter ablatio...
Mount Sinai’s Roxana Mehran, MD, named President of the American College of Cardiology
Dr. Roxana Mehran was appointed President of the American College of Cardiology, focusing on innovation, equity, and global collaboration to advance cardiovascular care. She aims to improve heart health for all through partnerships with major organizations.
Study illuminates benefits of red blood cell exchange in severe babesiosis
A multicenter study found that red blood cell exchange transfusion significantly improves clinical outcomes for patients hospitalized with severe babesiosis, a potentially life-threatening tick-borne infection. The procedure was associated with substantially lower risk of in-hospital death or readmission.
Long-term durability of acoramidis efficacy in transthyretin amyloid cardiomyopathy
Early and continuous acoramidis treatment resulted in sustained incremental reductions in all-cause mortality, cardiovascular-related mortality, and first cardiovascular hospitalization. The findings support the importance of early and continuous long-term treatment with acoramidis in transthyretin amyloid cardiomyopathy.
Switching from dulaglutide to tirzepatide boosts patient-reported well-being for people with type 2 diabetes
Researchers found that adults with type 2 diabetes who switched from dulaglutide to tirzepatide reported improved emotional responses and a greater quality of life. The study suggests that tirzepatide may offer broader benefits beyond glucose control, improving patients' physical and emotional well-being.
PSMA therapy delays hormone therapy in prostate cancer
A new study shows that PSMA therapy can delay the need for hormone therapy in prostate cancer patients by an average of 20 months. The therapy is effective in earlier stages of the disease, improving survival and quality of life for approximately two out of three patients.
Extended low-dose apixaban and superficial vein thrombosis
Extended low-dose apixaban effectively reduced symptomatic superficial vein thrombosis (SuVT) risk. Patients with enduring risk factors for SuVT benefited from this anticoagulation strategy.
Global trial supported by SickKids stem cell research shows targeted heart drug reduces obstructive HCM in youth
A global clinical trial led by SickKids has found that mavacamten improves blood flow and reduces obstruction in youth with hypertrophic cardiomyopathy (HCM), a genetic heart disease. The study's results offer hope to families avoiding open-heart surgery, setting the stage for precision therapeutics.
Direct comparison shows stroke protection devices during TAVR perform alike
The Emboliner device performed comparably to the Sentinel device in protecting against stroke and death in patients undergoing TAVR. The study found that both devices captured similar amounts of debris particles, with the Emboliner capturing three times as many larger particles.
Minimally invasive valve repair reduces heart failure hospitalizations in patients with severe tricuspid regurgitation
A minimally invasive procedure using a clip to repair the valve significantly reduced heart failure hospitalizations by 40% in patients with severe tricuspid regurgitation. The study, presented at the American College of Cardiology's Annual Scientific Session, showed improved long-term outcomes without crossover between treatment groups.
EMPEROR-preserved risk model and outcomes in the FINEARTS-HF trial
The EMPEROR-Preserved risk model demonstrated good performance in the FINEARTS-HF trial, showing that baseline risk does not modify the relative treatment effect of finerenone. Finerenone has been shown to have a significant benefit for heart failure patients.